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Abstract Rats with systemic carnitine deficiency induced
by treatment with trimethylhydraziniumpropionate (THP)
develop liver steatosis. This study aims to investigate the
mechanisms leading to steatosis in THP-induced carnitine
deficiency. Rats were treated with THP (20 mg/100 g) for 3
or 6 weeks and were studied after starvation for 24 h. Rats
treated with THP had reduced in vivo palmitate metabolism
and developed mixed liver steatosis at both time points.
The hepatic carnitine pool was reduced in THP-treated rats
by 65% to 75% at both time points. Liver mitochondria
from THP-treated rats had increased oxidative metabolism
of various substrates and of 
 

 
-oxidation at 3 weeks, but re-
duced activities at 6 weeks of THP treatment. Ketogenesis
was not affected. The hepatic content of CoA was increased
by 23% at 3 weeks and by 40% at 6 weeks in THP treated
rats. The cytosolic content of long-chain acyl-CoAs was in-
creased and the mitochondrial content decreased in hepato-
cytes of THP treated rats, compatible with decreased activity
of carnitine palmitoyltransferase I in vivo. THP-treated rats
showed hepatic peroxisomal proliferation and increased
plasma VLDL triglyceride and phospholipid concentrations
at both time points.  A reduction in the hepatic carnitine
pool is the principle mechanism leading to impaired hepatic
fatty acid metabolism and liver steatosis in THP-treated
rats. Cytosolic accumulation of long-chain acyl-CoAs is asso-
ciated with increased plasma VLDL triglyceride, phospholipid
concentrations, and peroxisomal proliferation.—
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Liver steatosis is a frequent finding in liver biopsies and
a frequent cause of asymptomatic elevation of transami-
 
nases (1). Several risk factors have been identified, among
them ingestion of certain drugs (2–5), alcohol abuse (6),
viral hepatitis (7), diabetes (8), increased body weight (8,
9), and intoxications (10). While impaired mitochondrial
 

 
-oxidation is considered to be the principle cause for mi-
crovesicular steatosis (11), the mechanisms leading to
macrovesicular steatosis have so far not been identified in
detail. As shown in 
 
Fig. 1
 
, important possibilities leading
to this finding include a decrease in VLDL export and/or
an increase in VLDL formation, which may result from
impaired mitochondrial fatty acid metabolism or from
other causes.
We have recently developed and characterized a rat
model with systemic carnitine deficiency (12). In this
model, carnitine deficiency is induced within 3 weeks by
feeding trimethylhydraziniumpropionate (THP), which
inhibits carnitine biosynthesis and increases renal excre-
tion of carnitine. Interestingly, rats treated with THP de-
velop combined micro- and macrovesicular liver steatosis
within 3 weeks but have no macro- or microscopic accu-
mulation of lipids in skeletal muscle or heart (12, 13).
Since carnitine is essential for transport of long-chain fatty
acids into the mitochondrial matrix (14), it can be specu-
lated that at least the microvesicular part of liver steatosis
in THP-treated rats could be caused by hepatic carnitine
deficiency. In support of this assumption, both in children
with primary systemic carnitine deficiency and in mice
with systemic carnitine deficiency (JVS mice), microvesic-
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ular liver steatosis has been reported (15, 16). However, at
least the macrovesicular part of liver steatosis in rats
treated with THP cannot be explained by an isolated de-
fect in mitochondrial 
 

 
-oxidation of fatty acids, suggesting
additional mechanisms.
Since the morphology of liver steatosis in THP-treated
rats resembles that found in certain types of steatotic livers
in humans, e.g., certain types of alcohol-induced liver ste-
atosis (17) or steatosis observed during administration of
amiodarone (18), knowledge about the mechanisms lead-
ing to liver steatosis in THP-treated rats may also be rele-
vant for understanding this disease in humans. We there-
fore decided to study the mechanisms leading to liver
steatosis in rats treated with THP for 3 or 6 weeks. Beside
the mechanisms leading to liver steatosis, we also investi-
gated adaptive changes secondary to a decrease in the he-
patic carnitine pool and to impaired in vivo mitochon-
drial 
 

 
-oxidation. Our studies demonstrate that hepatic
carnitine deficiency is the most important cause for liver
steatosis in THP-treated rats and suggest that reduced mi-
tochondrial fatty acid oxidation may be partially compen-
sated by increased peroxisomal fatty acid metabolism due
to proliferation of peroxisomes.
MATERIALS AND METHODS
 
Induction of carnitine deficiency and in 
vivo palmitate metabolism
 
The experiments have been reviewed and accepted by the
State Ethics Committee of animal research. Carnitine deficiency
was induced in male Sprague-Dawley rats by feeding vegetarian
food poor in carnitine (Kliba Futter 2435, Basel, Switzerland)
and THP (20 mg/100 g/day) for 3 or 6 weeks (n 
 

 
 6 rats for
each time point) (12). Control rats were kept for the same peri-
ods of time with the same rat chow ad libitum (n 
 

 
 12).
In order to investigate a potential toxic effect on mitochon-
drial metabolism by THP itself in vivo, rats (n
 

 
3 in each group)
were treated with THP (20 mg/100 g/day), with 
 
l
 
-carnitine (50
mg/100 g/day), or with the combination of THP and 
 
l
 
-carnitine
(same dosages) for 3 weeks.
Metabolism of palmitate was determined in vivo after 3 weeks of
treatment with THP by intraperitoneal injection of [
 
14
 
C]palmitate
and determination of exhaled 
 
14
 
CO
 
2
 
 as described previously (19).
 
Isolation of rat liver mitochondria
 
Rats were killed by decapitation and mitochondria were isolated
from the liver by differential centrifugation according to a previ-
ously described method (20). This method yields mitochondria of
Fig. 1. Hepatic metabolism of long-chain fatty acids. Palmitate and other long-chain fatty acids are activated by palmitoyl-CoA (PCS) on
the outer mitochondrial membrane, converted to palmitoylcarnitine by carnitine palmitoyltransferase I (CPT I), transported into the mito-
chondrial matrix and reconverted to palmitoyl-CoA by CPT II (see magnification). Palmitoyl-CoA is degraded to acetyl-CoA by the -oxida-
tion cycle. Acetyl-CoA can be converted to ketone bodies (major pathway) or be degraded in the Krebs cycle. Palmitoyl-CoA can also be
-oxidized by peroxisomes which produce medium-chain acyl-CoAs that are converted to the corresponding acyl-carnitines and can be metab-
olized to acetyl-CoA by mitochondria. In addition, cytosolic palmitoyl-CoA can also be used for the formation of triglycerides and phospho-
lipids, which are both substrates for the formation of VLDL particles. See text for additional explanations. CTL, carnitine-acylcarnitine
translocase, i.m., inner mitochondrial membrane, o.m., outer mitochondrial membrane.
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high purity with only minor contamination by peroxisomes or lyso-
somes (21). The mitochondrial protein content was determined us-
ing the biuret method with BSA as a standard (22). The content of
mitochondrial protein/g liver was determined by correcting for the
recovery of the mitochondria isolated using the activities of citrate
synthase and succinate dehydrogenase (21).
 
Oxidative metabolism of intact mitochondria
 
Oxygen consumption by freshly isolated liver mitochondria
was measured in a chamber equipped with a Clark-type oxygen
electrode (Yellow Springs Instruments, Yellow Springs, OH) at
30
 

 
C as described previously (23). The concentrations of the sub-
strates used were 20 mmol/l for 
 
l
 
-glutamate and succinate, 40
 

 
mol/l for palmitoyl-
 
l
 
-carnitine, 20 
 

 
mol/l for palmitoyl-CoA,
and 80 
 

 
mol/l for palmitate. All incubations with fatty acids con-
tained 5 mmol/l 
 
l
 
-malate, incubations with palmitoyl-CoA and
palmitate contained in addition 2 mmol/l 
 
l
 
-carnitine, and incu-
bations with palmitate contained in addition 250 
 

 
mol/l ATP
and 250 
 

 
mol/l CoASH.
 
In vitro mitochondrial 
 

 
-oxidation and formation 
of ketone bodies
 
The 
 

 
-oxidation of [1-
 
14
 
C] palmitic acid by liver mitochondria
was assessed as described by Fréneaux et al. (24) with some mod-
ifications described previously (25). This assay measures the for-
mation of acid-soluble products from mitochondrial palmitate
metabolism, which equals production of ketone bodies and citric
acid cycle intermediates (24).
Ketone body formation was measured using freeze-thawed mi-
tochondria according to Chapman et al. (26) with some modifi-
cations as described previously (25). The reactions were stopped
by adding 100 
 

 
l of 30% perchloric acid (w/v). After having re-
moved the precipitate by centrifugation, the supernatants were
analyzed for acetoacetate according to Olsen (27).
 
Activities of the enzyme complexes of the
respiratory chain
 
Complex I (NADH:decylubiquinone-1 oxidoreductase) was
determined spectrophotometrically as described by Veitch et al.
(28) with some modifications. Briefly, 0.1 mg mitochondria were
preincubated in 35 mmol/l potassium phosphate buffer pH 7.4,
5 mmol/l magnesium chloride, 2 mmol/l potassium cyanide,
and 60 
 

 
mol/l decylubiquinone at 30
 

 
C. The reaction was
started by the addition of 0.13 mmol/l NADH and the decrease
of absorption was recorded spectrophotometrically at 340 nm us-
ing rotenone as inhibitor.
Complex II (succinate:dichloroindophenol oxidoreductase)
was determined according to a previously described method (23).
This method is based on the reduction of dichloroindophenol by
complex II using succinate as a substrate. The reaction is followed
spectrophotometrically at 600 nm in the presence and absence of
the inhibitor thenoyltrifluoroacetone.
Complex III (ubiquinol:ferricytochrome c oxidoreductase) was
determined spectrophotometrically at 550 nm by the conversion of
ferricytochrome c to ferrocytochrome c using decylubiquinol as
substrate (29). The reaction velocity was assessed as the difference
in absorption with and without antimycine as inhibitor.
Complex IV (cytochrome c oxidase) activity was measured by
following the oxidation of ferrocytochrome c at 550 nm as de-
scribed by Wharton and Tzagaloff (30).
 
Determination of CoA and carnitine
 
Liver samples (about 50 mg/1 ml, prepared without thawing)
were homogenized in 3% perchloric acid and centrifuged for 5
min at 10,000 
 
g
 
. Mitochondria (100 
 

 
l corresponding to about
10 mg protein) were mixed with 20 
 

 
l 0.2 mol/l dithiothreitol
and precipitated with 1.88 ml 3.2% perchloric acid. The suspen-
sion was vortexed, kept on ice for 5 min, and then centrifuged
for 10 min at 10,000 
 
g
 
. This perchloric acid treatment yields an
Fig. 2. Liver steatosis in rats treated with THP for 3
weeks. Cryosections stained with Sudan Black for spe-
cific labeling of lipids. As shown in A (enlargement
64), lipids accumulate predominantly in zones 1 and
2 of the liver lobules, while zone 3 is spared. A higher
enlargement (Fig. 2B, enlargement 160) shows that
the size of the lipid droplets varies, small and larger
droplets can be detected in most hepatocytes, in par-
ticular in the periportal regions. Similar findings were
present after 6 weeks of treatment with THP. In com-
parison, livers from control animals contained no fat
(not shown). P, portal vein; C, central vein.
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acid soluble (supernatant) and an acid insoluble fraction (pellet).
The acid soluble fraction is used to measure free and acetyl-CoA
and, after alkaline hydrolysis, total acid soluble CoA. The differ-
ence between these values represents short chain acyl-CoA. Long
chain CoA is determined in the pellet after alkaline hydrolysis.
Total CoA refers to the sum of total acid soluble CoA and long-
chain acyl-CoA.
In these fractions, CoASH and acetyl-CoA, total acid soluble
CoA (supernatant), and long-chain acyl-CoA (pellet) were deter-
mined using the CoA recycling assay of Allred and Guy (31), with
some modifications in the work-up as described before (32).
Since the CoA recycling assay does not differentiate CoASH and
acetyl-CoA, acetyl-CoA was determined specifically using a radio-
enzymatic assay as described previously (33).
For the determination of carnitine, liver tissue was worked up
as described above for CoA. Plasma was also treated with perchlo-
ric acid (final concentration 3%) to obtain a supernatant and a
pellet. The determination of carnitine in these fractions was per-
formed using the radioenzymatic assay described by Brass and
Hoppel (34). Direct analysis of the supernatant yields free car-
nitine, and, after alkaline hydrolysis, total acid soluble carnitine.
The difference between free and total acid soluble carnitine is
the short-chain acylcarnitine fraction (up to a chain-length of
the acyl-group of about 10). Long-chain acylcarnitines were de-
termined in the pellet after alkaline hydrolysis. Addition of total
acid soluble and long-chain acylcarnitine yields total carnitine.
 
Lipid determination in livers
 
Lipids from rat livers were extracted according to the method
described by Bligh and Dyer (35). Briefly, about 100 mg of liver
tissue were homogenized in 2 ml 20 mmol/l potassium phos-
phate buffer, pH 7.4, and the lipids were extracted by the addi-
tion of 5.0 ml chloroform-methanol (1:1, v/v). The samples were
vortexed and incubated for 60 min under periodical stirring.
Then, 2.5 ml chloroform and 0.8 ml 0.74% potassium chloride
were added and the mixture centrifuged for 5 min at 500 
 
g
 
. The
lower phase was separated and washed with 1.5 ml of a mixture
containing 0.74% potassium chloride-chloroform-methanol
(94:96:6, v/v/v). The organic phase was then evaporated to dry-
ness and the lipid extract stored at 
 

 
20
 

 
C until analysis.
For lipid determination, liver extracts were resuspended in 250 
 

 
l
isopropanol. Total cholesterol, triacylglycerides, and free fatty acids
were measured using enzymatic methods and reagents from Wako
(Neuss, Germany). The measurements were calibrated using stan-
dards from Roche Diagnostics (Mannheim, Germany).
 
Determination of plasma lipids
 
Total cholesterol (TC), free cholesterol (FC), triacylglycerides
(TG), phospholipids (PL), HDL cholesterol (HDL-C), and free
fatty acids (FFA) were measured using enzymatic methods and
reagents from Wako (Neuss, Germany). The measurements were
performed on a Wako 30R automatic analyzer (Wako) and were
calibrated using standards from Roche Diagnostics (Mannheim,
Germany). Esterified cholesterol was calculated as the difference
between TC and FC.
The determination of the lipoprotein fractions was performed
by a combined ultracentrifugation-precipitation method (36,
37). VLDL were removed quantitatively by ultracentrifugation
using a TFT 56.6 rotor (Kontron, Germany) with adapters for 0.8
ml polycarbonate tubes. Five hundred microliters of plasma was
pipetted into tubes and 0.1 ml of 0.9% sodium chloride solution
was layered on top of the plasma. After centrifugation (18 h at
30,000 rpm, 10
 

 
C), the floating VLDL fraction was aspired with a
2 ml syringe until the supernatant was completely clear. The vol-
ume was reconstituted to the original weight with 0.9% saline.
 
LDL were precipitated in the infranatant using phosphotungstic
acid/magnesium chloride (PTA, Roche, Mannheim, Germany),
and HDL lipids were measured in the supernatant after LDL pre-
cipitation. Lipids in the LDL fraction were calculated as the dif-
ference between the concentrations in the density fraction d 
 

 
1.006 kg/l and the HDL fraction.
 
Cytochemical localization of catalase in liver sections
 
Livers from control rats and rats treated with THP for 3 weeks
were fixed by perfusion through the portal vein with a fixative
containing 0.25% glutaraldehyde and 2% sucrose in 0.1 M PIPES
buffer, pH 7.4. The tissue was cut into 70 
 

 
m sections with a DSK-
Microslicer (Dosaka EM Co., Kyoto, Japan). The sections were
incubated in alkaline diaminobenzidine (DAB) medium for cy-
tochemical visualization of catalase (38), followed by osmication
and embedding in Epon 812.
 
SDS-PAGE and immunoblotting
 
For Western blotting, tissues were homogenized in a buffer
containing 250 mM sucrose, 5 mM MOPS, 1 mM EDTA, 0.1%
ethanol, pH 7.4, using an Ultra-Turrax (IKA Labortechnik,
Staufen, Germany). Equal amounts of protein (20 
 

 
g per sam-
ple) were subjected to SDS-PAGE. After electrotransfer of the
polypeptides onto nitrocellulose, the sheets were incubated over-
night with the primary antibody at a concentration of 1 
 

 
g pro-
tein/ml. The polyclonal antibody against acyl-CoA oxidase
(AOX) was a generous gift of A. Völkl, Institute of Anatomy and
Cell Biology, University of Heidelberg. Its specificity was assessed
as described previously (39). After repeated washing, a peroxi-
dase conjugated goat anti-rabbit antibody (Sigma, München,
Germany) was added for 1 h at room temperature. The immu-
noreactive bands were visualized by enhanced chemolumines-
cence (ECL, Amersham International, Little Chalfont, England)
according to the manufacturer’s protocol.
The blots for subunit IV of cytochrome c oxidase and apolipopro-
tein B (apoB) were performed according to the method described
above. The polyclonal antibody against subunit IV of cytochrome c
oxidase was obtained from Molecular Probes (Juro Supply, Lucerne,
Switzerland) and used at a dilution of 0.5 
 

 
g/ml. The polyclonal
antibody against apoB was obtained from LabForce AG (4208
Nunningen, Switzerland) and used at a dilution of 0.5 
 

 
g/ml.
 
Determination of acyl-CoA oxidase activity
 
Acyl-CoA oxidase activity was determined according to a previ-
ously described method (40). This method is based on the produc-
tion of hydrogen peroxide by the action of acyl-CoA oxidase, which
is measured spectrophotometrically at 502 nm using dichlorofluo-
rescein diacetate as a chromophore. Briefly, 50 mg of frozen liver tis-
sue were homogenized in 20 mmol/l potassium phosphate buffer,
pH 7.4, and the volume made up to 2.0 ml. One hundred microliters
of this homogenate were preincubated in 1.9 ml of 10 mmol/l
potassium phosphate buffer pH 7.4 containing 0.05 mg
2
 
	
 
,7
 
	
 
dichlorfluorescein diacetate, 5.2 mg sodium azide, 74 mU
horseradish peroxidase, and 0.01% TritonX at 37
 

 
C for 5 min. The
reaction was started by the addition of 15 
 

 
mol/l palmitoyl-CoA and
the increase in absorbance was recorded spectrophotometrically
over 3 min at 502 nm. Activities were calculated using an extinction
coefficient of 91,000 l 
 

 
 mol
 

 
1
 
 
 

 
 cm
 

 
1
 
.
 
Statistics
 
Data are presented as mean 
 


 
 SD. Groups were compared using
the Student’s 
 
t
 
-test (comparison of two groups) or ANOVA followed
by Tukey’s protected Student’s 
 
t
 
-test (
 

 
2 groups). Since the values
of control animals were generally not different between 3 and 6
weeks, they were pooled unless indicated otherwise.
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RESULTS
The studies were carried out to elucidate the principle
mechanisms leading to liver steatosis in rats with systemic
carnitine deficiency due to treatment with THP.
Rats were treated with THP for 3 or 6 weeks and studied
after starvation for 24 h. As shown in 
 
Fig. 2
 
, and in agree-
ment with previous studies (12, 13), rats treated with THP
for 3 weeks developed micro- and macrovesicular liver ste-
atosis predominantly in zone I and II of the liver lobules.
Similar findings were obtained after 6 weeks of treatment
with THP (results not shown).
Palmitate metabolism was assessed in vivo in rats treated
with THP for 3 weeks and corresponding control rats by
injecting l-[
 
14
 
C]palmitate ip and measuring the amount of
 
14
 
CO
 
2
 
 exhaled over the next 2 h. The percentage of radio-
activity exhaled was decreased in THP treated rats (28.2 
 


 
6.3% vs. 54.8 
 


 
 8.2% of the dose injected, 
 
P
 
 
 

 
 0.05), com-
patible with reduced hepatic metabolism of long-chain
fatty acids. Accordingly, the hepatic lipid content was in-
creased significantly (
 
P
 
 
 

 
 0.05) in rats treated with THP
for 6 weeks for all lipid classes investigated [cholesterol
0.77 
 


 
 0.09 vs. 0.58 
 


 
 0.09 mg/g liver (THP-treated vs.
control), triglycerides 4.63 
 


 
 2.78 vs. 1.54 
 


 
 0.46 mg/g liver,
and free fatty acids 0.80 
 


 
 0.09 vs. 0.58 
 


 
 0.02 
 

 
mol/g liver].
As can be seen in Fig. 1, reduced metabolism of long-
chain fatty acids can be due to impaired activation of fatty
acids, impaired transport of fatty acids into the mitochon-
drial matrix, impaired 
 

 
-oxidation and/or an impaired
function of the respiratory chain.
As expected from the mechanism by which THP re-
duces the body carnitine content, namely inhibition of
carnitine biosynthesis and increased renal excretion of
carnitine (12), the liver carnitine pool was reduced in
THP-treated rats, showing a drop by 
 

 
70% in comparison
to control rats (
 
Table 1
 
). Since carnitine is essential for
the function of CPT I (Fig. 1), this finding may explain
liver steatosis in THP-treated rats. Interestingly, both the
 
short-chain acylcarnitine to free carnitine and the long-
chain acylcarnitine to free carnitine ratios were increased
in livers of rats treated for 6 weeks, compatible with accu-
mulation of 
 

 
-oxidation intermediates due to impaired
 

 
-oxidation of fatty acids (32).
Since 
 

 
-oxidation is primarily a mitochondrial function,
these findings prompted us to study the function of the
respiratory chain and oxidative metabolism of fatty acids
in isolated mitochondria (
 
Table 2
 
). Surprisingly, state-
3 oxidation rates tended to be higher in rats treated with
THP for 3 weeks but were generally decreased in rats
treated for 6 weeks. This decrease was observed particularly
for succinate, palmitic acid, palmitoyl-CoA, and palmitoyl-
carnitine, suggesting a defect in the activity of complex II
of the electron transport chain and of 
 

 
-oxidation. It is note-
worthy that the experiments with palmitate and palmitoyl-
CoA were performed in the presence of exogenous car-
nitine. When no exogenous carnitine was added to these
substrates, state-3 oxidation rates were not different between
mitochondria of control and THP-treated rats, and were ap-
proximately only 10% of the rates obtained with control mito-
chondria in the presence of exogenous carnitine.
In order to exclude a major effect of carnitine defi-
ciency on the mitochondrial electron transport chain, the
activity of the enzyme complexes of the electron transport
chain was determined. As shown in 
 
Table 3, the activities
of complexes I to IV were unchanged or increased after 3
weeks of treatment with THP, when compared with con-
TABLE 1. Liver and plasma carnitine pools
Control
(n  12)
THP 3 weeks
(n  6)
THP 6 weeks
(n  6)
Liver (nmol/g liver
wet weight)
Free Cn 266 
 73 74 
 31a 75 
 16a
SCA Cn 127 
 52 38 
 20a 51 
 17a
LCA Cn 50 
 21 14 
 12a 26 
 8a
Total Cn 442 
 75 125 
 3a 153 
 27a
SCA Cn/Free Cn 0.48 
 0.13 0.51 
 0.15 0.68 
 0.15a
LCA Cn/Free Cn 0.19 
 0.07 0.19 
 0.12 0.35 
 0.09a,b
Plasma (mol/l)
Free Cn 29.8 
 9.3 5.6 
 0.8a 4.6 
 1.6a
SCA Cn 33.4 
 12.9 5.4 
 0.8a 4.9 
 1.3a
LCA Cn 9.3 
 1.5 1.6 
 0.7a 1.6 
 2.7a
Total Cn 72.6 
 24.9 12.6 
 0.7a 11.0 
 4.2a
Cn, carnitine; LCA Cn, long-chain acylcarnitine; SCA Cn, short-chain
acylcarnitine. Control and THP-treated rats (20 mg/100 g body weight)
were studied after 3 or 6 weeks of treatment in the fasted state. The car-
nitine pools were determined by a radioenzymatic assay as described in
Materials and Methods. Data are presented as mean 
 SD. 
a P  0.05 versus control.
b P  0.05 THP 6 weeks versus THP 3 weeks.
TABLE 2. State 3 oxidation rates by isolated rat liver mitochondria
Control
(n  12)
THP 3 weeks
(n  6)
THP 6 weeks
(n  6)
l-Glutamate (20 mM) 82 
 24 101 
 17 80 
 23
Succcinate (20 mM) 150 
 40 207 
 31a 123 
 31b
Palmitoyl-l-carnitine (40 M) 82 
 26 116 
 18a 62 
 13b
Palmitoyl-CoA (20 M) 83 
 17 97 
 28 68 
 14b
Palmitate (80 M) 46 
 10 63 
 14a 29 
 10a,b
Control and THP-treated rats (20 mg/100 g body weight) were
studied after 3 or after 6 weeks of treatment in the fasted state. Mito-
chondria were isolated by differential centrifugation and state 3 oxida-
tion rates were determined in the presence of the substrates indicated
using a Clark-type oxygen electrode as described in Materials and
Methods. Units are natoms oxygen  minute1  milligram of mito-
chondrial protein1. Results are presented as mean 
 SD.
a P  0.05 versus control rats.
b P  0.05 THP 6 weeks versus THP 3 weeks.
TABLE 3. Activities of enzyme complexes of the electron transport 
chain in isolated rat liver mitochondria
Control 
(n  12)
THP 3 weeks
(n  6)
THP 6 weeks
(n  6)
Complex I 17.5 
 6.8 22.3 
 12.6 15.5 
 5.6
Complex II 12.0 
 3.0 15.1 
 5.9a 10.5 
 4.1b
Complex III 1780 
 440 1560 
 340 1560 
 420
Complex IV 419 
 149 381 
 195 367 
 129
Control and THP treated rats (20 mg/100 g body weight) were
studied after 3 or 6 weeks of treatment in the fasted state. Enzyme activ-
ities were determined using spectrophotometric methods as described
in Materials and Methods. Units are mU  mg mitochondrial
protein1. Data are presented as mean 
 SD.
a P  0.05 versus control rats.
b P  0.05 THP 6 weeks versus THP 3 weeks.
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trol values. After 6 weeks of treatment, the activity of com-
plex II was significantly decreased, whereas the activities
of complex I, III, and IV were not altered in comparison
to control rats. These findings agree well with the data ob-
tained by the oxygen electrode.
Since reduced fatty acid oxidation could not be ex-
plained entirely by a reduced activity of the electron trans-
port chain, we investigated the function of CPT I and of
mitochondrial -oxidation (Table 4). A direct toxic effect
of THP on mitochondrial fatty acid metabolism was ex-
cluded, since THP did not impair CPT I activity or mito-
chondrial -oxidation up to a concentration of 500 mol/
l and the addition of l-carnitine to THP prevented the de-
velopment of liver steatosis in vivo (Fig. 3). CPT I activity,
which can be rate-limiting for mitochondrial -oxidation
(41), was not different between mitochondria from THP-
treated or control animals at 3 weeks, but showed a signif-
icant reduction in THP-treated rats at 6 weeks. Consider-
ing mitochondrial -oxidation, no differences between
THP-treated and control rats were observed after 3 weeks
of treatment, whereas -oxidation was reduced in rats
treated with THP for 6 weeks. In contrast, ketogenesis was
not affected at both time points. In agreement with keto-
genesis, the -hydroxybutyrate concentrations in liver and
plasma were not different between control and THP-
treated rats.
The results obtained so far show a decrease in the he-
patic carnitine pool, impaired metabolism of palmitic
acid, accumulation of hepatic fat at 3 weeks and 6 weeks
of treatment with THP, and impaired hepatic mitochon-
drial -oxidation and activity of CPT I at 6 weeks. These
results therefore suggest that carnitine deficiency, which is
present at both time points, is the major cause for liver ste-
atosis in THP-treated rats, whereas decreased mitochon-
drial -oxidation/CPT I activity may contribute at 6 weeks
of treatment with THP. In order to investigate the conse-
quences of carnitine deficiency in more detail, we deter-
mined the cytosolic and the mitochondrial CoA pools (Ta-
ble 5). Expressed per gram of liver, the CoA pool was
increased in THP treated rats at both time points. This in-
crease could be explained by a rise in free and acetyl-CoA,
whereas the short- and long-chain acyl-CoA contents were
not different from control rats. In contrast to total liver,
the mitochondrial CoA content was decreased in THP-
treated rats both when expressed per mitochondrial protein
content or per mitochondria contained in 1 g of liver. This
decrease could be explained by a reduced mitochondrial
content in short- and long-chain CoAs. Consequently, the cy-
tosolic CoA content (calculated as the difference between the
total content and the content in the mitochondria per g liver)
was increased in THP-treated rats and this increase was found
for all CoA fractions determined.
Mitochondrial dysfunction can be associated with sec-
ondary hepatic changes such as mitochondrial prolifera-
tion (21, 23). Mitochondrial proliferation was assessed by
determining the mitochondrial protein content per gram
of liver and by performing Western blots of subunit IV of
cytochrome c oxidase. Mitochondrial protein content was
not significantly different between control and THP
treated rats (111 
 25 mg /g in control rats, and 89 
 16
and 103 
 23 mg/g in rats treated with THP for 3 and 6
weeks, respectively). In addition, the protein content of
TABLE 4. In vitro -oxidation and ketogenesis
Control 
(n  12)
THP 3 weeks
(n  6)
THP 6 weeks
(n  6)
CPT I 347 
 74 309 
 53 263 
 56a
-Oxidation 0.86 
 0.22 0.84 
 0.2 0.45 
 0.14a,b
Ketogenesis 15.0 
 4.0 16.7 
 6.3 16.4 
 5.7
Ketone bodies
Liver 1.96 
 0.4 2.11 
 0.5 1.94 
 0.1
Plasma 903 
 189 829 
 172 805 
 165
Control rats and THP treated rats (20 mg/100 g body weight)
were studied after 3 or 6 weeks of treatment in the fasted state. Activi-
ties were determined using radioactive substrates as described in Mate-
rials and Methods. Units are mU  mg mitochondrial protein1 for
CPT I activity, -oxidation and ketogenesis and nmol  mg liver wet
weight1 and mol  l1 for ketone bodies in liver and plasma, respec-
tively. Data are presented as mean 
 SD.
a P  0.05 versus control rats.
b P  0.05 THP 6 weeks versus THP 3 weeks.
Fig. 3. Effect of l-carnitine on liver steatosis in rats treated with
THP for 3 weeks. Cryosections stained with Sudan Black for specific
labeling of lipids (enlargement 44). Treatment of l-carnitine (50
mg/100 g/day for 3 weeks) is not associated with accumulation of
fat (A). Similar to Fig. 2, treatment with THP (20 mg/100 g/day for
3 weeks) is associated with fat accumulation in the periportal re-
gion (B). The addition of l-carnitine (50 mg/100 g/day for 3
weeks) to THP (20 mg/100 g/day for 3 weeks) prevents the accu-
mulation of fat almost completely (C).
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COX subunit IV, as assessed by Western blotting, was not
different between THP and control rats (results not
shown), excluding mitochondrial proliferation.
When mitochondrial fatty acid metabolism is impaired,
peroxisomal proliferation could be a consequence due to
hepatic accumulation of long-chain fatty acids and fatty
acid metabolites that may stimulate peroxisome prolifera-
tor-activated receptor (PPAR) (42). Indeed, a significant
panlobular peroxisomal proliferation occurred in livers of
THP-treated rats (Fig. 4). In agreement with these results,
peroxisomal fatty acyl-CoA oxidase activity and protein
content were both increased in THP-treated rats (Fig. 5).
A third consequence of decreased mitochondrial fatty
acid oxidation could be an increase in the hepatic VLDL
production. This was assessed indirectly by measuring the
plasma lipid composition. As shown in Table 6, VLDL tri-
glycerides and phospholipids were all increased in THP-
treated versus control rats, which may reflect increased
hepatic availability of activated fatty acids (as shown
above) with increased hepatic VLDL synthesis. On the
other hand, Western blot analysis revealed that the he-
patic content of apoB was not different between THP-
treated and control rats (results not shown).
DISCUSSION
Our study demonstrates that THP-treated rats have an
70% reduction in the hepatic carnitine content, re-
duced in vivo metabolism of palmitate, liver steatosis, ac-
cumulation of long-chain acyl-CoAs in the cytosol of the
hepatocytes, hepatic proliferation of peroxisomes, and in-
creased plasma VLDL.
The study was designed to find out the mechanisms
leading to micro- and macrovesicular steatosis THP-
treated rats. Liver steatosis was present already at 3 weeks
of treatment, a time point when THP-treated rats had de-
veloped systemic carnitine deficiency, and had reduced in
vivo metabolism of palmitate, whereas oxidative metabo-
lism and -oxidation of isolated liver mitochondria was
normal or even higher in mitochondria from THP-treated
as compared with control rats. Since THP has no apparent
toxicity on liver mitochondria, liver steatosis is explained,
at least at this early time point, entirely by a reduction in
the hepatic carnitine pool.
After 6 weeks of treatment with THP, oxidative metabo-
lism of different substrates (including fatty acids) as well
as -oxidation and activity of CPT I were reduced in THP-
treated rats, suggesting that impaired mitochondrial func-
tion could contribute to the development of liver steato-
sis. Although the study was not designed to find out the
mechanisms leading to mitochondrial dysfunction at this
time point, it can be speculated that it may reflect changes
in the lipid composition of mitochondrial membranes
and/or oxidative damage to mitochondria, as observed in
other animal models with alterations in hepatic fatty acid
metabolism (43) or liver steatosis (44, 45).
In THP-treated rats, the hepatic content of long-chain
acyl-CoAs was increased at 3 and 6 weeks, compatible with
a decreased cytosolic conversion of long-chain acyl-CoAs
to the respective carnitine derivatives due to carnitine de-
ficiency and/or reduced activity of CPT I (see Fig. 1 for
Fig. 4. Hepatic peroxisomal proliferation in rats treated with
THP for 3 weeks. Peroxisomes were stained with the alkaline DAB
method for cytochemical localization of catalase. Hepatocytes of
rats treated with THP contain an increased number of peroxi-
somes. In comparison to lipid accumulation (Fig. 2), the increase
in the number of peroxisomes shows no significant lobular gradi-
ent (enlargement 640).
TABLE 5. Liver CoA pool
Control 
(n  12)
THP 3 weeks
(n  6)
THP 6 weeks
(n  6)
Total liver
CoASH  acetyl-CoA 223 
 73 301 
 89a 365 
 64a
Short-chain acyl-CoA 68 
 57 63 
 27 68 
 47
Long-chain acyl-CoA 90 
 31 102 
 32 97 
 13
Total CoA 380 
 84 466 
 61a 528 
 90a
Liver cytosol
CoASH  acetyl-CoA 172 
 63 nd 323 
 62a
Short-chain acyl-CoA 26 
 15 nd 52 
 23a
Long-chain acyl-CoA 55 
 16 nd 75 
 10a
Total CoA 251 
 46 nd 446 
 43a
Liver mitochondria
CoASH 381 
 156 nd 365 
 64
Acetyl-CoA 76 
 15 nd 51 
 22a
Short-chain acyl-CoA 379 
 129 nd 159 
 91a
Long-chain acyl-CoA 315 
 92 nd 212 
 55a
Total CoA 1160 
 160 nd 793 
 108a
Control and THP treated rats (20 mg/100 g body weight) were
studied after 3 or 6 weeks of treatment in the fasted state. CoASH and
acyl-CoAs (except acetyl-CoA) were determined fluorimetrically, and
acetyl-CoA by a radioenzymatic method as described in Materials and
Methods. Units are nmol  g liver wet weigh1 (total liver and liver cy-
tosol) or nmol  g mitochondrial protein1. The cytosolic CoA con-
tent was calculated by subtracting the mitochondrial from the total
liver content as described in Materials and Methods. Data are pre-
sented as mean 
 SD.
a P  0.05 versus control rats.
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explanation). Peroxisomal proliferation may result from
stimulation of PPAR by accumulated fatty acids and fatty
acid derivatives in THP-treated rats (42), and may represent a
mechanism to compensate for decreased mitochondrial
metabolism of fatty acids. In support of this interpretation, a
significant increase in the surface density of peroxisomes
has been described in humans with liver steatosis (46).
Since peroxisomes produce also medium chain acyl-CoAs
during -oxidation, the observed increase in the cytosolic
content of short-chain acyl-CoAs and of the short-chain
acylcarnitine to carnitine ratio may result from increased
peroxisomal metabolism of long-chain fatty acids. Medium-
chain acylcarnitines may serve as additional substrates for mi-
tochondrial -oxidation in THP-treated rats since they can
enter the mitochondria without the action of CPT I.
In THP-treated rats, carnitine deficiency was associated
with a significant increase in the cytosolic CoA content of
the hepatocytes, whereas the mitochondrial content de-
creased. CoA is synthesized from pantothenate, cysteine,
and ATP, with the rate-limiting step being phosphoryla-
tion of pantothenate located in the cytosol (47). Mito-
chondria obtain CoA either by endogenous biosynthesis
[the final steps in CoA synthesis are also found in mito-
chondria (48)] or by transport across the inner mitochon-
drial membrane by a specific transport system (49). In
comparison, degradation of CoA appears to be a cytosolic
process (50). Interestingly, rats treated with clofibrate, a
ligand for PPAR leading to peroxisomal proliferation
(51), also reveal an increase in the hepatic CoA pool (52–
54), suggesting that an increase in the hepatic CoA pool
and peroxisomal proliferation may somehow be con-
nected. The rise in the hepatic CoA pool by clofibrate has
clearly been shown to result from increased biosynthesis
(54), and the distribution of CoA between the mitochon-
dria and the cytosol was not affected in clofibrate-treated
rats (53). In contrast, in THP treated rats, the total he-
patic CoA pool is increased due to a rise in the cytosolic
content of CoA, whereas the mitochondrial content is de-
creased. Since the changes in the hepatic CoA pool could
already be observed at 3 weeks of treatment with THP, a
Fig. 5. Protein expression and activity of acyl-CoA oxidase.
Similar to earlier observations, the Western blot of liver homo-
genate with polyclonal antibodies against acyl-CoA oxidase
(AOX) reveals three bands (58, 59). These three bands corre-
spond to AOX subunits A (71.9 kDa), B (51.7 kDa), and C
(20.5 kDa). All three bands exhibited a significant (P  0.05)
augmentation in livers from THP-treated rats. The densito-
metric analysis yielded 3.52 
 1.29 versus 1.00 
 0.43 for band
A (THP-treated vs. control), 1.55 
 0.12 versus 1.00 
 0.27 for
band B, and 1.70 
 0.39 versus 1.00 
 0.17 for band C. The
activity for AOX was increased 1.5-fold, corresponding well
with the densitometric results for bands B and C.
TABLE 6. Plasma lipid and lipoprotein analysis
CON (n  6) THP (n  6)
Lipids and glycerol
Triglycerides 0.47 
 0.12 0.58 
 0.12
Phospholipids 1.17 
 0.17 1.51 
 0.35a
Cholesterol 0.12 
 0.03 0.13 
 0.02
Free fatty acids 0.72 
 0.10 0.71 
 0.20
Glycerol 0.023 
 0.004 0.023 
 0.005
VLDL
Triglycerides 0.49 
 0.15 0.72 
 0.15a
Phospholipids 0.10 
 0.03 0.16 
 0.03a
Cholesterol 0.11 
 0.02 0.08 
 0.03
LDL
Phospholipids 0.23 
 0.03 0.31 
 0.14
Cholesterol 0.25 
 0.05 0.28 
 0.12
HDL
Triglycerides 0.15 
 0.01 0.15 
 0.02
Phospholipids 0.90 
 0.09 1.09 
 0.31
Cholesterol 0.52 
 0.07 0.55 
 0.18
Control and THP treated rats (20 mg/100 g body weight) were
studied after weeks of treatment in the fasted state. Plasma lipoproteins
were isolated using a combined centrifugation/precipitation tech-
nique and lipids were analyzed enzymatically as described in Materials
and Methods. Data are presented as mean 
 SD. Units are mmol/l for
free fatty acids and g  l1 for all other lipids or metabolites.
a P  0.05 THP versus CON.
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time point when -oxidation was not impaired, these al-
terations in the CoA pool did probably not affect signifi-
cantly hepatic fatty acid metabolism in THP-treated rats.
In THP-treated rats, the phospholipid and triglyceride
contents were increased in the VLDL fraction in plasma
and also per gram of liver, whereas the hepatic apoB con-
tent was unchanged. These findings are compatible with
increased loading of VLDL with triglycerides and phos-
pholipids in the liver, which is most probably a conse-
quence of increased cytosolic availability of fatty acids and
acyl-CoAs due to impaired mitochondrial fatty acid metab-
olism. Hepatic accumulation of triglycerides has been as-
sociated with the development of macrovesicular steatosis
of the liver (9, 11). Since isolated inhibition of mitochon-
drial fatty acid metabolism is considered to result in mi-
crovesicular steatosis (11), secondary accumulation of cy-
tosolic triglycerides and phospholipids in the presence of
initial mitochondrial damage may explain the develop-
ment of a mixed type of liver steatosis over time.
Despite reduced in vivo metabolism of palmitate and
decreased activity of CPT I, as well as mitochondrial -oxi-
dation in THP-treated rats, the plasma and liver -hydroxy-
butyrate concentrations were not different from control
rats. Hepatic long-chain fatty acid metabolism is con-
trolled at two sites, namely at CPT I and mitochondrial
HMG-CoA synthase (55, 56), both of them regulated en-
zymes. Since ketogenesis was assessed specifically and was
not different between mitochondria from THP-treated
and control rats, the activity of the HMG-CoA synthase
can be assumed to be identical in THP-treated and con-
trol rats. The observed decrease of palmitate metabolism
in THP rats in vivo, which is explained primarily by he-
patic carnitine deficiency and, at 6 weeks, also reduced ac-
tivity of CPTI/mitochondrial -oxidation, could therefore
be expected to result in decreased hepatic production of
ketone bodies, e.g., -hydroxybutyrate. Indeed, in agree-
ment with reduced CPT I activity/mitochondrial -oxida-
tion, liver mitochondria from THP-treated rats contained
less acetyl-CoA than control mitochondria. On the other
hand, the plasma and liver -hydroxybutyrate concentra-
tions were not different between THP-treated and control
rats. Among the possibilities to explain this discrepancy
are decreased consumption of ketone bodies by periph-
eral tissues such as skeletal muscle, or increased produc-
tion of ketone bodies by extrahepatic tissues such as kid-
neys in THP-treated rats. These two possibilities are
unlikely, however, since not only plasma, but also the he-
patic -hydroxybutyrate concentration was unaffected by
treatment with THP. The most likely possibility is there-
fore that during starvation, the HMG-CoA cycle becomes
rate-limiting for ketogenesis. During starvation, the activ-
ity of CPT I increased due to a decrease in the hepatic
concentration of malonyl-CoA, an endogenous inhibitor
of CPT I (55). This increase in CPT I activity during star-
vation may be sufficient so that ketogenesis is controlled
solely by the HMG-CoA cycle, as suggested by our find-
ings. In support of this interpretation, starved rats with
acute cholestasis have reduced production of ketone bod-
ies and a reduced activity of HMG-CoA synthase, the rate-
limiting enzyme of the HMG-CoA cycle, while the func-
tion of CPT I is normal (25). On the other hand, ketogen-
esis is reduced in JVS mice, an animal model with severe
systemic carnitine deficiency (57). The hepatic carnitine
content in JVS mice is less than 5% of normal, limiting the
activity of CPT I to a higher extent than in THP-treated
rats. In JVS mice, ketogenesis was maximal at carnitine
concentrations above 100 nmol/g liver wet weight (57), a
value which is just reached in THP-treated rats.
We conclude that a reduction in the hepatic carnitine
pool is the principle mechanism leading to impaired he-
patic fatty acid metabolism and liver steatosis after 3 weeks
of treatment with THP. After 6 weeks of treatment, im-
paired activity of CPT I and mitochondrial -oxidation
may contribute. Cytosolic accumulation of fatty acids and
long-chain acyl-CoAs is associated with increased plasma
VLDL triglyceride and phospholipid concentrations and
peroxisomal proliferation.
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